Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the financial results for the quarter and financial year ended March 31, 2026.
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SPARC reported total income of Rs 1,89,000 lakhs for FY2026, a massive jump from Rs 7,356 lakhs in FY2025, driven primarily by a one-time income of Rs 1,84,002 lakhs from a USFDA Priority Review Voucher (PRV) granted for Sezaby® and subsequently sold for USD 195 million in April 2026. Core pharmaceutical R&D operations generated only Rs 3,915 lakhs in regular revenue (down from Rs 7,177 lakhs). The company turned profitable with PAT of Rs 1,55,320 lakhs versus a loss of Rs 34,251 lakhs in the prior year. Annual EPS came in at Rs 47.86 per share. An exceptional item of Rs 1,236 lakhs was recognized in Q3 for new labour code implementation costs. The balance sheet shows equity recovered to positive Rs 1,33,882 lakhs from negative Rs 21,695 lakhs last year, though current borrowings increased significantly to Rs 55,614 lakhs.
The PRV windfall creates an artificial profit spike masking ongoing losses in core operations. Operating cash burn of Rs 23,877 lakhs continues to be concerning. Shareholders should treat FY2026 earnings as exceptional and one-time in nature rather than sustainable improvement.